Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Role of the Maternal Gut Microbiota in Immune Activation at the Maternal-Foetal Interface: Impact on Preeclampsia and Offspring's Immune Development

Project description

Changes in the microbiota during pregnancy and development of preeclampsia

Preeclampsia (PE), or toxaemia, is a condition late in pregnancy characterised by high blood pressure, protein in urine and swelling in the legs, feet and hands. PE is a leading cause of morbidity and mortality in pregnancy. The pathogenesis remains unknown, but it is thought to be associated with the loss of immune-tolerance at the maternal–foetal interface. At present, preeclampsia can neither be reliably predicted nor prevented. The EU-funded DaPhNls project will investigate how changes in the gut microbiota during pregnancy impact immune responses at the maternal–foetal interface and try to elucidate the consequences on pregnancy outcomes and offspring immune development. The translational relevance of the findings will be evaluated in a large patient cohort, with the identification of potential biomarkers and molecular mechanisms amenable to therapeutic intervention.

Objective

Preeclampsia is a leading cause of morbidity and mortality in pregnancy. Although the pathogenesis remains largely elusive, it is thought to reside in loss of immune-tolerance at the maternal-foetal interface. At present, preeclampsia can neither be reliably predicted nor prevented.
Scope of this research project is to investigate how changes in microbiota during pregnancy impact immune responses at the maternal-foetal interface, and to determine the consequences on pregnancy outcomes as well as development of offspring’s immunity. Translational relevance of findings specifically to preeclampsia will be evaluated in a large cohort of patients, with implications potentially arising from the identification of novel biomarkers and of molecular mechanisms amenable to pharmacologic intervention.
The Experienced Researcher (ER) of this study, Dr. Silvia Giugliano, is an accomplished immunologist with primary expertise in organ-specific immune responses to microbes. Formerly an independent academic researcher in the USA, she was recently recruited to work at the European Institute of Oncology (Milan, Italy) by Prof. Maria Rescigno, a world-class expert in the field of microbiota and mucosal immunity, specifically to advance the hosting laboratory’s expertise in placental immunity.
There is an urgent call for actions aimed at improving women’s health, and it is incumbent on the scientific community to tackle this issue. Thus, the present proposal captures the current zeitgeist and social responsibility of Science. Complementary, prime expertise between the ER and host laboratory will create a synergistic enterprise, ideally suited to the pursuit of this ambitious research goal. Findings and hypotheses generated in this process will kick off additional, related projects, and will be disseminated beyond the boundaries of the scientific community and to public audiences. The ER will emerge with new skills, and the capability to transition to independence in her home country.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF-EF-SE - Society and Enterprise panel

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2017

See all projects funded under this call

Coordinator

HUMANITAS MIRASOLE SPA
Net EU contribution
€ 168 277,20
Address
VIA MANZONI 56
20100 Rozzano (Mi)
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 168 277,20